visible, thus allowing unequivocal identification of the capillary segment in-between. He termed the observed contractile population as "Rouget cells".
The term pericytes was later coined by Zimmermann in 1923 . He demonstrated that pericytes were: a) present around capillaries in a wide range of species including fish, amphibians, reptiles, birds and mammals; b) continuous with smooth muscle cells of arteries and veins; c) highly branched with distinctive cytoplasmic processes within each capillary bed. Moreover, Zimmermann held that contraction of these cells controlled capillary permeability and distinguished three subgroups of pericytes, depending on the type of vessel pericytes are located at, but already considered the existence of a continuum with countless forms of differentiation.
desmin, nestin, platelet derived growth factor receptor- (PDGFR-), aminopeptidase A, aminopeptidase N (CD 13), sulfatide or nerve/glial antigen-2 (NG2) proteoglycan (Morikawa et al., 2002) (Fig. 1) . Pericytes on normal capillaries typically express desmin, but not alpha smooth muscle actin, whereas smooth muscle cells on arterioles and pericytes on venules are immunoreactive for both (Nehls and Drenckhahn, 1993; Morikawa et al., 2002) . Other reports have suggested that alpha smooth muscle actin may be considered a general marker for pericytes (Hellstrom et al., 1999; Ohlsoon et al., 1999) .
The balance between endothelial cells and pericytes
The balance between the number of endothelial cells and pericytes seems to be highly controlled. Potential regulators include soluble factors acting in an autocrine and/or paracrine manner, mechanical forces secondary to blood flow and blood pressure, as well as homotypic and heterotypic cell contacts.
Severals molecules are involved in the control and modulation of the interactions occurring between pericytes and endothelial cell, such as PDGF-B, transforming growth factor beta (TGF-), vascular endothelial growth factor (VEGF), angiopoietins (Angs), signaling pathways involving Notch and ephrins (Hughes, 2008; von Tell et al., 2006) .
Endothelial production of PDGF-B is required for pericyte recruitment
Endothelial cells secrete PDGF-B and pericytes express PDGFR- (Betsholtz, 2004) , suggesting a paracrine mode of interaction between these two cell types (Fig. 2) . PDGF-B promotes pericyte precursor cell proliferation and migration and mice deficient for PDGF-B or PDGFR- die during embryonic development with widespread microvascular defects, consisting in vessel dilatation and microaneurysms. In most tissues of these animals pericyte association with vessels is drastically reduced (Betsholtz, 2004) . Endothelial cells of the sprouting capillaries in the PDGF-B deficient mice were unable to attract PDGFRB--positive progenitors of pericytes. Failure to recruit pericytes during development leads to vascular instability and regression (Benjamin et al., 1998; Leveen et al., 1994; Lindbloom et al., 2003) . Greenberg et al. (2008) demonstrated that under conditions of PDGF-mediated angiogenesis, VEGF abolished pericyte coverage of vascular sprouts, leading to vessel destabilization. VEGFmediated activation of VEGFR-2 suppressed PDGFR- signaling, through the induction of a VEGFR-2/ PDGFR- complex (Fig.  2) .
TGF-    1 contributes to the differentiation of precursor cells into pericytes
When mesenchymal cells are co-cultured with endothelial cells or treated with TGF-1, they express smooth muscle cell markers, indicating differentiation of precursor cells into pericytes or smooth muscle cells (Darland and D'Amore, 2001) . Mice deficient for endoglin, a TGF-1 co-receptor, display reduced association with smooth muscle cells and pericytes (Li et al., 1999) . TGF-1 inhibits endothelial cell proliferation and migration, and mice deficient for TGF-1 signaling components show dilated and irregularly shaped microvessels (Lebrin et al., 2005) . Overall, these data indicate that TGF-1 appears to be instrumental for the de novo induction of pericytes by regulating differentiation of pericyte progenitors.
VEGF induces proliferation and migration of pericytes and pericyte-derived VEGF promotes endothelial cell survival
VEGF directly induces proliferation and migration of pericytes in hypoxic conditions (Yamagishi et al., 1999) and also indirectly stimulate pericyte recruitment via endothelial cell production of nitric oxide (NO). In turn, NO promotes mural precursor cell migration in vitro and pericyte recruitment to tumor vessels in vivo (Kashiwagi et al., 2005) . Treatment with VEGF inhibitors causes pericytes to become closely associated with surviving tumor vessels in Lewis lung carcinomas, RIP-Tag2 tumors (Inai et al., 2004) and other tumor models Willett et al., 2004) . Darland et al. (2003) demonstrated that pericytes cocultured with endothelial cells produce VEGF that may act in a juxtacrine/paracrine manner as a survival and/or stabilizing factor for endothelial cells. Moreover, they observed VEGF gene expression in developing retinal vasculature in pericytes contacting newly formed microvessels.
Pericyte-derived Ang-1 promotes endothelial cell survival and Ang-2 acts as a destabilizing factor and the balance of Ang-1 and Ang-2 signaling regulates pericyte recruitment
The Angs family consists of Ang-1, -2, and the orthologous Ang-3 in mouse and Ang-4 in human. All Angs bind the endothelial-specific receptor tyrosine kinase Tie-2 (also known as TEK) and play a critical role in endothelial sprouting, vessel wall remodeling and mural cell recruitment (Thurston, 2003) .
Ang-1 is produced by pericytes and smooth muscle cells, activates endothelial Tie-2, maximizes interactions between endothelial cells and pericytes and is expressed behind the leading edge of angiogenic vessels, a position consistent with vessel maturation (Sundberg et al., 2002) . Mice deficient for either Ang-1 or Tie-2 die during embryonic development with vascular defects similar to those observed for PDGF-B deficient mice (Jones et al., 2001) . Ultrastructural analysis suggests that Tie-2-knock out blood vessels lack mural cells (Patan, 1998) . In PDGF-B deficient mice, recombinant Ang-1 restored the vascular structure and permeability in the growing retinal vasculature (Uemura et al., 2002) . Moreover, Ang-1 also counteracts VEGF-induced endothelial leakiness (Thurston et al., 1999) .
Ang-2 is expressed by endothelial cells located at the leading edge of proliferating vessels (Maisonpierre et al., 1997) and acts as a destabilizing factor which is restricted to endothelial cells in areas of vascular remodeling and binds Tie-2 without inducing signal transduction (Maisonpierre et al., 1997) .
Expression of both Ang-2 and Tie-2 in pericytes has been also reported (Wakui et al., 2006; Cai et al., 2008) . VEGF increases production of Ang-2, and overexpression of Ang-2, which binds to Tie-2 in competition with Ang-1, by endothelial cells results in dissociation of pericytes from vessels (Zhang et al., 2003) , reduces pericyte coverage and destabilizes vessels within the tumor even in the presence of VEGF stimulation (Cao et al., 2007) . Moreover, transgenic mice overexpressing Ang-2 in the retina develop dense vascular networks with reduced pericyte coverage (Feng et al., 2007) . De Palma et al. (2005) demonstrated that monocytes expressing Tie-2 (TEMs) are a distinct haemopoietic lineage of proangiogenic cells and distinguished a subpopulation of tumor stroma-derived mesenchymal progenitor cells representing a primary source of tumor pericytes.
NG2 and Notch-3 mediate pericyte-endothelial interactions
Immature pericytes express the NG2 proteoglycan during early stages of angiogenesis and soluble NG2 promotes endothelial cell motility and angiogenesis forming a complex with galectin-3 and 31 integrin on the cell surface (Fukushi et al., 2004) . Both blocking by antibodies as well as knocking out of the gene encoding NG2 abrogated vascular growth (Ozerdem and Stallcup, 2004) . Virgintino et al. (2007) have shown that microvessels of the fetal human telencephalon are characterized by a continuous layer of NG2-positive pericytes, which tightly invest endothelial cells in the earliest stages of vessel growth.
Notch signaling is a highly conserved pathway, initially discovered in Drosophila development (Baron et al., 2002) . There are four Notch receptors (Notch 1-4) and five ligands (Jagged-1, and -2, Delta 1, -3, -4) (Iso et al., 2003) . All the receptors and ligands are expressed in at least one vascular compartment, e.g. arteries, veins, capillaries, muscle cells or pericytes.
Notch signaling is required for remodeling the primary vascular plexus into the hierarchy of mature vascular beds and maintaining arterial fate (Alva and Iruela-Arispe, 2004). The Notch-3 receptor is highly expressed in pericytes and disruption of Notch-3 signaling in Notch-3 -/-mutant mice results in enlarged vessels due to the lack of pericytes (Wang et al., 2007) . Patients suffering from CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) syndrome, pathology associated with mutations of Notch-3, present vessels lacking pericytes (Louvi et al., 2006) . In dental pulp, perivascular cells mainly express Notch-3 (Lovschall et al., 2007) and in the retina pericytes express also Notch-3 (Claxton and Fruttiger, 2004) . More recently, Liu et al. (2009) showed that knockdown by small interfering RNA revealed that Notch-3 signaling is necessary for endothelial-dependent mural cell differentiation, and Notch-3 contributes to the pro-angiogenic capability of mural cells co-cultured with endothelial cells.
Ephrins and Eph receptors
The discovery that members of the ephrins (Eph) family are differentially expressed in arteries and veins from very early stages of development has been one of the first indications that artery-vein identity is intrinsically programmed. Eph-B2 is expressed in arterial endothelial cells. The principal receptor for Eph-B2, Eph-B4, displays a reciprocal expression pattern in embryonic veins (Bratley-Siders and Chen, 2004) . Mutations of the Eph-B2 and of Eph-B4 both lead to early embryonic lethality (Wang et al., 1998; Adams et al., 1999; Gerety et al., 1999; . Remodeling of the primary vascular plexus into arteries and veins was arrested in both mutants, suggesting important roles for Eph-B2/Eph-B4 interactions on arterial and venous endothelial cells, respectively.
Ephrin-B2 is a critical regulator of mural cell migration, spreading and adhesion during vessel wall assembly (Foo et al., 2006) . More recently, Salvucci et al. (2009) reported that Eph-B is a critical mediator of postnatal pericyte to endothelial cell assembly into vascular tubes. Furthermore, inhibition of Eph-B activity prevents assembly of pericytes and endothelial cells.
The role of pericytes in angiogenesis
During the initial phase of angiogenesis, activated pericytes in parent vessels bulge, shorten their processes and increase their volume, an intense cell proliferation occurs, pericytes project into the perivascular spaces, their basement membrane is disrupted and fragmented and appear detached from the vessel wall (DiazFlores et al., 1992) . Although initially endothelial cell sprouts may form without pericyte involvement, pericytes are among the first cells to invade newly vascularized tissues and locate at the growing front of the endothelial sprouts by determining the location of sprout formation and by guiding newly formed vessels (Nehls et al., 1992) . Individual pericytes can be found at the tips of angiogenic sprouts in the corpus luteum, where pericytes are the first vascular cells to invade the granulose fold of the ruptured follicle, and in tumors (Amselgruber et al., 1999; Gerhardt and and Stallcup, 2003) . Rajantie et al. (2004) showed that bone marrow-derived hematopoietic progenitors cells CD11b + and CD45 + expressing the pericyte marker NG2 were located in close proximity to blood vessels in a subcutaneous B16-F10 melanoma model. Bone marrow-derived PDGFR- + /Sca-1 + progenitor pericytes have been demonstrated in mouse model of pancreatic islet tumorigenesis, which were able to differentiate into mature pericytes expressing the markers NG2 and alpha smooth actin (Song et al., 2005) . Virgintino et al. (2007) demonstrated in the human fetal telencephalon that growing microvessels are formed by a pericyte-driven angiogenic process in which endothelial cells are preceded and guided by migrating pericytes.
Overall, these data suggest the existence of a mutual interplay between endothelial cells and pericytes in the direction of the angiogenic process, assigning to the pericytes a putative morphogenetic role.
Pericytes as targets in tumor therapy
In pathological conditions in which angiogenic activity is enhanced, such as tumors, pericytes are located near blood vessels at the growing front of tumors, where angiogenesis is most active and show morphological abnormalities (Schlingemann et al., 1990; Wesseling et al., 1995; Morikawa et al., 2002) . Moreover, 
Betsholtz, 2003; Morikawa et al., 2002).
It has long believed that endothelial tube formation is followed by investment of pericytes, which use endothelial cell sprouts as migration clues. Accordingly, pericytes are recruited by differentiation from surrounding mesenchymal precursors or by migration from the mural wall of the adjacent vessel (Gerhardt and Betsholtz, 2003) . In this way, pericytes suppress endothelial growth (Orlidge and D'Amore, 1987) and migration (Sato and Rifkin, 1989) . There is a striking coincidence of pericyte investment and microvessel stabilization (von Tell et al., 2006; Bergers and Song 2005) and pericyte investment has also been directly implicated in conferring capillary resistance to regression in vivo (Benjamin et al., 1998) . Clinical evidence for a stabilizing function of pericyte was offered by the finding that the development of microaneurysms of retinal capillaries, as a symptom of diabetic retinopathy, was correlated with an initial loss of intramural pericytes (Kuwabara and Cogan, 1963) .
In 1990, Blood and Zetter wrote that: "Formation of a basement membrane and investment of capillaries with pericytes are generally associated with the end of the proliferative stage and the beginning of the mature or quiescent stage of capillary function". More recently, Stratman et al. (2009) have demonstrated that endothelial cell-pericyte interactions regulate increased expression of basement membrane protein genes and proteins, such as fibronectin and laminin, as well as integrins that recognize the remodeled matrices to control this process and these changes occur specifically in endothelial cellpericyte co-cultures and not in endothelial cell only cultures.
Alternatively, pericytes can invade tissues in the absence of endothelial cells and can form tubes enabling the subsequent penetration of endothelial cells (Ozerdem pericyte deficiency could be partly responsible for vessel abnormalities in tumor blood vessels (Gerhardt and Semb, 2008) and partial dissociation of pericytes (Hobbs et al., 1998; Hashizume et al., 2000) contribute to increased tumor vascular permeability.
VEGF inhibition eliminates tumor vessels without removing pericytes (Morikawa et al., 2002) . Antiangiogenic treatment directed against endothelial cells using VEGF inhibitors induces the regression of tumor vessels and decreases tumor size (Baluk et al., 2005) , leading to vessel normalization, characterized by increased pericyte coverage, tumor perfusion and chemotherapeutic sensitivity (Jain, 2005) . Moreover, removal of VEGF inhibition causes tumor re-growth due to the fact that pericytes provide a scaffold for the rapidly re-growing of tumor vessels (Mancuso et al., 2006) .
Pericytes have been indicated as putative targets in the pharmacological therapy of tumors by using the synergistic effect of anti-endothelial and anti-pericytic molecules. Removal of pericyte coverage leads to exposed tumor vessels, which may explain the enhanced effect of combining inhibitors that target both tumor vessels and pericytes. Bergers et al. (2003) showed that combined treatment or pre-treatment with anti-PDGF-B/PDGFBR- reducing pericyte coverage increases the success of anti-VEGF treatment in the mouse RIP1-TAG2 model.
However, extensive regression of endothelial cells was not observed in tumors after inhibition of PDGFR- signaling (Abramsson et al., 2003) . STI571 (Gleevec, Imatinib), which targets PDGFRs and other receptor tyrosine kinases, did not reduce vascular density when given alone but did augment the effects of VEGF inhibitors (Bergers et al., 2003) . After treatment of RIP1-TAG-2 tumors and Lewis lung carcinomas with AG-013737 or VEGF-Trap, surviving pericytes may become more tightly associated with endothelial cells or have no apparent association with tumor vessels (Inai et al., 2004) . Treatment of RIP1-TAG2 tumors with anti-PDGFR- antibody for three weeks reduces pericytes, increases endothelial cell apoptosis but does not seem to reduce tumor vascular density (Song et al., 2005) . Similarly, the receptor tyrosine kinase inhibitor SU6668, which also affects PDGFR- signaling, detaches and reduces pericytes in RIP1-TAG2 and xenotransplanted tumors, thereby restricting tumor growth Shaheen et al., 2001) . Sennino et al. (2007) demonstrated that treatment with a novel selective PDGF-B blockade DNA aptamer AX102 that blocks the action of PDGF-B led to progressive reduction of pericytes in Lewis lung carcinomas. More recently, Murphy et al. (2010) generated a series of selective type II inhibitors of PDGFR- and B-RAF targets for pericyte recruitment and endothelial survival, respectively and they demonstrated that dual inhibition of both PDGFR- and B-RAF exerted synergistic antiangiogenic activity in both zebrafish and murine models of angiogenesis.
Several other important studies with the aim to target pericytes have been conducted in experimental tumor models (Pietras and Hanahan, 2005; Maciag et al., 2008; Lu et al., 2010) , and even in a human trial in advanced renal cell carcinoma (Haisnworth et al., 2007) .
We have recently demonstrated that combined targeting of pericytes and endothelial tumor cells with a combination of a peptide ligand of aminopeptidase A (APA), disovered by phage display technology for deliver of liposomal doxorubicin (DXR) to perivascular tumor cells, and aminopeptidase N (APN)-targeted liposomal DXR enhances anti-tumor efficacy of liposomal chemotherapy in human neuroblastoma-bearing mice (Loi et al., 2010) .
Concluding remarks
Pericytes are critical cells in vascular biology. They intervene at different levels of blood vessel formation, being involved in endothelial cell stimulation and guidance as well as endothelial stabilization and maturation. Signaling pathways operating in endothelial cell-pericyte cross-talk are currently being investigated and will provide crucial information on the paracrine molecular mechanisms controlling capillary formation (Fig. 3) . This point is of critical interest in the physiopathological and clinical approach to degenerative vasculopathies as well as tumor angiogenesis. Finding drugs that allow manipulation of pericyte/endothelial cell interactions will provide physicians with a potent tool capable of controlling and blocking vascular proliferation and permeability. Increase of pericyte recruitment to stabilize new vessels will potentially ameliorate vascular disorders, such as diabetic retinopathy. In addition, a stable capillary microvasculature may represent an important prerequisite for preventing tumor cell dissemination. The future use of molecules interfering with the endothelial cell/pericyte unit will be also of interest in tissue engineering as well as the development of multi-tissue organs. Further studies are needed to highlight further aspects of pericyte molecular biology and physiology. 
